Clinical Policy: Elagolix (Orilissa)
Reference Number: CP.PHAR.136
Effective Date: 08.28.18
Last Review Date: 11.19
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Elagolix (Orilissa™) is a gonadotropin-releasing hormone (GnRH) receptor antagonist.

FDA Approved Indication(s)
Orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Orilissa is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Endometriosis Pain (must meet all):
      1. Diagnosis of pain due to endometriosis;
      2. Prescribed by or in consultation with a gynecologist;
      3. Age ≥ 18 years;
      4. Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced (a or b):
         a. A non-steroidal anti-inflammatory drug (see Appendix B for examples);
         b. A progestin-containing oral or depot injectable contraceptive agent (see Appendix B for examples);
      5. Member does not have osteoporosis;
      6. Dose does not exceed 400 mg per day.

   Approval duration: 6 months for 200 mg twice daily; 12 months for 150 mg once daily

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.
II. Continued Therapy
   A. Endometriosis Pain (must meet all):
      1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
      2. Member is responding positively to therapy as evidenced by improvement in dysmenorrhea, dyspareunia, pelvic pain/induration/tenderness, or size of endometrial lesions;
      3. If request is for a dose increase, new dose does not exceed 400 mg per day.
   Approval duration: up to 6 months for 200 mg twice daily; up to 12 months for 150 mg once daily
   Total duration of therapy should not exceed 6 months for 200 mg twice daily or 24 months for 150 mg once daily.

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration
   GnRH: gonadotropin-releasing hormone
   OATP: organic anion transporting polypeptide

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs: ibuprofen, naproxen, fenoprofen, ketoprofen, mfenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam</td>
<td>Varies – refer to specific prescribing information</td>
<td>Varies – refer to specific prescribing information</td>
</tr>
<tr>
<td>Progestin-containing oral contraceptives: norethindrone, ethinyl estradiol +</td>
<td>1 tablet PO QD</td>
<td>1 tablet/day</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum Dose</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>(desogestrel, ethynodiol diacetate, drospirenone, etonogestrel, levonorgestrel, norelgestromin, norethindrone, norgestimate, or norgestrel); estradiol valerate + dienogest; mestranol + norethindrone</td>
<td>IM: 150 mg every 13 weeks&lt;br&gt;SC: 104 mg every 12 to 14 weeks</td>
<td>IM: 150 mg/3 months&lt;br&gt;SC: 104 mg/3 months</td>
</tr>
<tr>
<td>Depot injection progestin contraceptives: medroxyprogesterone acetate (Depo-Provera®, Depo-SubQ Provera 104®)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Pregnancy
  - Known osteoporosis
  - Severe hepatic impairment
  - Concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil)

- Boxed warning(s): None reported

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endometriosis pain</td>
<td>150 mg PO QD or 200 mg PO BID</td>
<td>150 mg/day x 24 months or 400 mg/day x 6 months</td>
</tr>
</tbody>
</table>

VI. Product Availability

Tablets: 150 mg, 200 mg

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.28.18</td>
<td>11.18</td>
</tr>
<tr>
<td>08.22.19</td>
<td>11.19</td>
</tr>
</tbody>
</table>

4Q 2019 annual review: no significant changes; references reviewed and updated.
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.
Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.